The Better Assessment of Illness Study for Delirium Severity: Study Design, Procedures, and Cohort Description.


Journal

Gerontology
ISSN: 1423-0003
Titre abrégé: Gerontology
Pays: Switzerland
ID NLM: 7601655

Informations de publication

Date de publication:
2019
Historique:
received: 06 03 2018
accepted: 25 05 2018
pubmed: 23 7 2018
medline: 18 5 2019
entrez: 23 7 2018
Statut: ppublish

Résumé

To describe the design, procedures, and cohort for the Better ASsessment of ILlness -(BASIL) study, which is conducted to develop and test new delirium severity measures, compare them with existing measures, and examine related clinical outcomes. Prospective cohort study with 1 year follow-up of study participants at a large teaching hospital in Boston, Massachusetts. After brief cognitive testing and the Delirium Symptom Interview, delirium and delirium severity were rated daily in the hospital using the Confusion Assessment Method (CAM) and CAM-Severity score, the Delirium Rating Scale-Revised-98 (DRS-R-98), and the Memorial Delirium Assessment Scale (MDAS). Other key study variables included comorbidity, physical function (basic and instrumental activities of daily living [ADL]), ratings of subjective health and well-being, and clinical outcomes (length of stay, 30 day rehospitalization, nursing home admission, healthcare utilization). Follow-up interviews occurred at 1- and 12-month with patients and families. In 42 patient interviews, inter-rater reliability for key variables was assessed. Of 768 eligible patients approached, 469 were screened and 352 enrolled, yielding an overall study response rate of 67% for potentially eligible participants. The mean participant was 80.3 years old (SD 6.8) and 203 (58%) were female. The majority of patients were medically complex with Charlson Comorbidity Scores ≥2 (192 patients, 55%), and 102 (29%) met criteria for dementia. Inter-rater reliability assessments (n = 42 pairs) were high for overall ratings of presence or absence of delirium by CAM (κ = 1.0), delirium severity by DRS-R-98 and MDAS (weighted kappa, κ = 1.0 for each) and for ADL impairment (κ = 1.0). For eligible participants at each time point, 278 out of 308 (90%) completed the 1-month follow-up and 132 out of 256 (53%) have completed the 12-month follow-up to date, which is still in progress. Among those who completed interviews, there was only 1-3% missing data on most major outcomes (delirium, basic ADL, and readmission). The BASIL study presents an innovative effort to advance the conceptualization and measurement of delirium severity. Unique strengths include the diverse cohort with complete high quality data and longitudinal follow-up, along with detailed collection of multiple delirium measures daily during hospitalization.

Sections du résumé

BACKGROUND/OBJECTIVES
To describe the design, procedures, and cohort for the Better ASsessment of ILlness -(BASIL) study, which is conducted to develop and test new delirium severity measures, compare them with existing measures, and examine related clinical outcomes.
METHODS
Prospective cohort study with 1 year follow-up of study participants at a large teaching hospital in Boston, Massachusetts. After brief cognitive testing and the Delirium Symptom Interview, delirium and delirium severity were rated daily in the hospital using the Confusion Assessment Method (CAM) and CAM-Severity score, the Delirium Rating Scale-Revised-98 (DRS-R-98), and the Memorial Delirium Assessment Scale (MDAS). Other key study variables included comorbidity, physical function (basic and instrumental activities of daily living [ADL]), ratings of subjective health and well-being, and clinical outcomes (length of stay, 30 day rehospitalization, nursing home admission, healthcare utilization). Follow-up interviews occurred at 1- and 12-month with patients and families. In 42 patient interviews, inter-rater reliability for key variables was assessed.
RESULTS
Of 768 eligible patients approached, 469 were screened and 352 enrolled, yielding an overall study response rate of 67% for potentially eligible participants. The mean participant was 80.3 years old (SD 6.8) and 203 (58%) were female. The majority of patients were medically complex with Charlson Comorbidity Scores ≥2 (192 patients, 55%), and 102 (29%) met criteria for dementia. Inter-rater reliability assessments (n = 42 pairs) were high for overall ratings of presence or absence of delirium by CAM (κ = 1.0), delirium severity by DRS-R-98 and MDAS (weighted kappa, κ = 1.0 for each) and for ADL impairment (κ = 1.0). For eligible participants at each time point, 278 out of 308 (90%) completed the 1-month follow-up and 132 out of 256 (53%) have completed the 12-month follow-up to date, which is still in progress. Among those who completed interviews, there was only 1-3% missing data on most major outcomes (delirium, basic ADL, and readmission).
CONCLUSION
The BASIL study presents an innovative effort to advance the conceptualization and measurement of delirium severity. Unique strengths include the diverse cohort with complete high quality data and longitudinal follow-up, along with detailed collection of multiple delirium measures daily during hospitalization.

Identifiants

pubmed: 30032141
pii: 000490386
doi: 10.1159/000490386
pmc: PMC6335161
mid: NIHMS976375
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

20-29

Subventions

Organisme : NIA NIH HHS
ID : R01 AG051658
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG044518
Pays : United States
Organisme : NIA NIH HHS
ID : K24 AG035075
Pays : United States
Organisme : NIA NIH HHS
ID : K07 AG041835
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG057955
Pays : United States
Organisme : NIA NIH HHS
ID : R24 AG054259
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG031720
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG030618
Pays : United States

Informations de copyright

© 2018 S. Karger AG, Basel.

Références

J Pain Symptom Manage. 1997 Mar;13(3):128-37
pubmed: 9114631
J Am Geriatr Soc. 2015 Dec;63(12):2463-2471
pubmed: 26662213
JAMA. 1963 Sep 21;185:914-9
pubmed: 14044222
J Am Med Dir Assoc. 2012 Nov;13(9):818.e1-10
pubmed: 22999782
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
JAMA. 2017 Sep 26;318(12):1161-1174
pubmed: 28973626
Psychol Med. 1994 Feb;24(1):145-53
pubmed: 8208879
J Am Geriatr Soc. 2008 May;56(5):823-30
pubmed: 18384586
J Clin Psychiatry. 2006;67 Suppl 2:40-5
pubmed: 16602814
J Am Geriatr Soc. 2004 Oct;52(10):1744-9
pubmed: 15450055
Aging Ment Health. 2010 Jul;14(5):543-55
pubmed: 20480420
Arch Intern Med. 2012 Sep 24;172(17):1324-31
pubmed: 23403619
J Am Geriatr Soc. 2001 May;49(5):516-22
pubmed: 11380742
Methods Inf Med. 1993 Nov;32(5):382-7
pubmed: 8295545
Neurology. 2012 Jun 5;78(23):1860-7
pubmed: 22573626
Psychol Med. 1991 Aug;21(3):785-90
pubmed: 1946866
Lancet. 2014 Mar 8;383(9920):911-22
pubmed: 23992774
Ann Intern Med. 2014 Apr 15;160(8):526-533
pubmed: 24733193
Int Psychogeriatr. 2004 Sep;16(3):275-93
pubmed: 15559753
J Neuropsychiatry Clin Neurosci. 2001 Spring;13(2):229-42
pubmed: 11449030
Ann Intern Med. 1990 Dec 15;113(12):941-8
pubmed: 2240918
Crit Care Med. 1986 Aug;14(8):754-5
pubmed: 3087704
Arch Intern Med. 2008 Jan 14;168(1):27-32
pubmed: 18195192
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Qual Life Res. 2012 Apr;21(3):475-86
pubmed: 21874314
J Am Geriatr Soc. 2017 Jan;65(1):51-58
pubmed: 27898172
Neurology. 2012 Mar 6;78(10):765-6; author reply 766
pubmed: 22391608
J Am Geriatr Soc. 2012 Nov;60(11):2121-6
pubmed: 23039310
Psychol Assess. 2016 Oct;28(10):1166-1171
pubmed: 26691504
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
J Am Geriatr Soc. 2011 Nov;59 Suppl 2:S241-3
pubmed: 22091567
J Am Geriatr Soc. 2002 May;50(5):850-7
pubmed: 12028171
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914

Auteurs

Tammy T Hshieh (TT)

Aging Brain Center, Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts, USAthshieh@bwh.harvard.edu.
Department of Medicine, Division of Aging, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USAthshieh@bwh.harvard.edu.

Tamara G Fong (TG)

Aging Brain Center, Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts, USA.
Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

Eva M Schmitt (EM)

Aging Brain Center, Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts, USA.

Edward R Marcantonio (ER)

Department of Medicine, Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

Madeline L D'Aquila (ML)

Aging Brain Center, Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts, USA.

Jacqueline Gallagher (J)

Department of Medicine, Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

Guoquan Xu (G)

Aging Brain Center, Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts, USA.

Yun R Guo (YR)

Aging Brain Center, Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts, USA.

Tatiana F Abrantes (TF)

Aging Brain Center, Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts, USA.

Sylvie E Bertrand (SE)

Aging Brain Center, Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts, USA.

Richard N Jones (RN)

Department of Psychiatry and Human Behavior, Department of Neurology, Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA.

Sharon K Inouye (SK)

Aging Brain Center, Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts, USA.
Department of Medicine, Division of Gerontology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH